Using an adaptive model to trial a new treatment for rare kidney disease

IgA nephropathy is a rare form of kidney disease. There is currently no drug or treatment available but there is hope on the horizon. An adaptive trial model is now being used to investigate a new drug being developed by Novartis, after showing promising results in the lab. Professor Jonathan Barratt, an expert in IgA Nepropathy, explains how the adaptive design of the study is helping to streamline the clinical development process. He also highlights UK successes of recruiting the first global patient for the study and being joint top recruiting country. Find out more about how the NIHR supports the delivery of Complex and Innovative Design (CID) clinical trials and studies: https://www.nihr.ac.uk/partners-and-industry/industry/run-your-study-in-the-nhs/complex-innovative-trials.htm Subscribe to the NIHRtv YouTube channel at https://www.youtube.com/NIHRtv Follow NIHR on social media • Twitter https://twitter.com/NIHRresearch • Facebook https://www.facebook.com/OfficialNIHR • LinkedIn https://www.linkedin.com/company/nihr_2/